Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
The companies plan to start a pivotal Phase 3 trial in the coming months
The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Subscribe To Our Newsletter & Stay Updated
